key: cord-0984253-m05onac1
authors: Alugubelli, Yugendar R.; Geng, Zhi Zachary; Yang, Kai S.; Shaabani, Namir; Khatua, Kaustav; Ma, Xinyu R.; Vatansever, Erol C.; Cho, Chia-Chuan; Ma, Yuying; Blankenship, Lauren; Yu, Ge; Sankaran, Banumathi; Li, Pingwei; Allen, Robert; Ji, Henry; Xu, Shiqing; Liu, Wenshe Ray
title: The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors
date: 2021-12-21
journal: bioRxiv
DOI: 10.1101/2021.12.18.473330
sha: d714e68cf28fe80932b6e3791515883c54416666
doc_id: 984253
cord_uid: m05onac1

Boceprevir is an HCV NSP3 inhibitor that has been explored as a repurposed drug for COVID-19. It inhibits the SARS-CoV-2 main protease (MPro) and contains an α-ketoamide warhead, a P1 β-cyclobutylalanyl moiety, a P2 dimethylcyclopropylproline, a P3 tert-butyl-glycine, and a P4 N-terminal tert-butylcarbamide. By introducing modifications at all four positions, we synthesized 20 boceprevir-based MPro inhibitors including PF-07321332 and characterized their MPro inhibition potency in test tubes (in vitro) and human host cells (in cellulo). Crystal structures of MPro bound with 10 inhibitors and antiviral potency of 4 inhibitors were characterized as well. Replacing the P1 site with a β-(S-2-oxopyrrolidin-3-yl)-alanyl (opal) residue and the warhead with an aldehyde leads to high in vitro potency. The original moieties at P2, P3 and the P4 N-terminal cap positions in boceprevir are better than other tested chemical moieties for high in vitro potency. In crystal structures, all inhibitors form a covalent adduct with the MPro active site cysteine. The P1 opal residue, P2 dimethylcyclopropylproline and P4 N-terminal tert-butylcarbamide make strong hydrophobic interactions with MPro, explaining high in vitro potency of inhibitors that contain these moieties. A unique observation was made with an inhibitor that contains an P4 N-terminal isovaleramide. In its MPro complex structure, the P4 N-terminal isovaleramide is tucked deep in a small pocket of MPro that originally recognizes a P4 alanine side chain in a substrate. Although all inhibitors show high in vitro potency, they have drastically different in cellulo potency in inhibiting ectopically expressed MPro in human 293T cells. All inhibitors including PF-07321332 with a P4 N-terminal carbamide or amide have low in cellulo potency. This trend is reversed when the P4 N-terminal cap is changed to a carbamate. The installation of a P3 O-tert-butyl-threonine improves in cellulo potency. Three molecules that contain a P4 N-terminal carbamate were advanced to antiviral tests on three SARS-CoV-2 variants. They all have high potency with EC50 values around 1 μM. A control compound with a nitrile warhead and a P4 N-terminal amide has undetectable antiviral potency. Based on all observations, we conclude that a P4 N-terminal carbamate in a boceprevir derivative is key for high antiviral potency against SARS-CoV-2.

structure, the P4 N-terminal isovaleramide is tucked deep in a small pocket of M Pro that originally recognizes a P4 alanine side chain in a substrate. Although all inhibitors show high in vitro potency, they have drastically different in cellulo potency in inhibiting ectopically expressed M Pro in human 293T cells. All inhibitors including PF-07321332 with a P4 N-terminal carbamide or amide have low in cellulo potency. This trend is reversed when the P4 N-terminal cap is changed to a carbamate. The installation of a P3 O-tert-butyl-threonine improves in cellulo potency. Three molecules that contain a P4 N-terminal carbamate were advanced to antiviral tests on three SARS-CoV-2 variants. They all have high potency with EC50 values around 1 µM. A control compound with a nitrile warhead and a P4 N-terminal amide has undetectable antiviral potency. Based on all observations, we conclude that a P4 N-terminal carbamate in a boceprevir derivative is key for high antiviral potency against SARS-CoV-2.

COVID-19 is the currently ongoing pandemic that is caused by the coronavirus SARS-CoV-2 and has no effective medication for treatment. To address this emergency, a large variety of drug repurposing research has been conducted to identify approved medications that might be potentially used as COVID-19 treatments. [1] [2] [3] [4] [5] Significant part of this research has been targeting the SARS-CoV-2 main protease (M Pro ). [6] [7] [8] [9] [10] [11] [12] M Pro is a peptide fragment of two translation products pp1a and pp1ab of the SARS-CoV-2 RNA genome after the virus infects human cells. Both pp1a and pp1ab are very large polypeptides that need to undergo proteolytic hydrolysis to form a number of nonstructural proteins (nsps). These nsps are essential for the virus to its genome replication in host cells, evasion from the host immune system, and packaging of new virions for infection of new host cells. 13 Intervention of proteolytic hydrolysis of pp1a and pp1ab is considered as a viable approach to stop SARS-CoV-2 infection. There are two internal peptide fragments from pp1a and pp1b that function as cysteine proteases to hydrolyze all nsps. One is M Pro and the other papain-like protease (PL Pro ) . As the main protease for this proteolytic process, M Pro processes the majority of nsps. It is also more conserved than PL Pro . M Pro genes in SARS-CoV and SARS-CoV-2 share 96% sequence identity. 2 Targeting M Pro for drug discovery will likely generate broad spectrum antivirals for coronaviruses. So far, a number of approved small molecule drugs have been confirmed as potent M Pro inhibitors. One of which is boceprevir. [14] [15] [16] Boceprevir is a peptidyl inhibitor of HCV NSP3. 17 HCV NSP3 is a serine protease. Boceprevir contains an a-ketoamide warhead that forms a reversible covalent adduct with its active site serine for high inhibition potency. 18 Besides the a-ketoamide warhead, boceprevir contains a P1 b-cyclobutylalanyl moiety, a P2 dimethylcyclopropylproline, a P3 tert-butylglycine, and a P4 N-terminal tert-butylcarbamide. Boceprevir has been shown as a potent inhibitor of M Pro in multiple publications. 1, 14-16 Its interactions with M Pro have also been structurally characterized using X-ray protein crystallography. 14-16, 19, 20 Although its discovery as a potent M Pro inhibitor created excitement about its potential use as a COVID-19 treatment, boceprevir has moderate antiviral activity against SARS-CoV-2 and displays very low potency to inhibit M Pro in a human cell host. 14, 15, 21 In this work, we report a systematic structure-activity relationship (SARS) study of boceprevir-based molecules for improved cellular and antiviral potency against the SARS-CoV-2 M Pro .

The Design and Synthesis of MPI29-47 and PF-07321332. In total, we designed 19 inhibitors as shown in Figure 1 . The Pfizer compound PF-07321332 is included in our analysis due to its close similarity to boceprevir. 22 M Pro contains four binding pockets in its active site to interact with the P1, P2, P4, and P3' amino acid residues in a substrate. The P1 residue in a substrate is strictly glutamine. Past efforts in developing M Pro inhibitors have been either using a P1 b-(S-2oxopyrrolidin-3yl)-alanyl (opal) residue in a peptidyl inhibitor or a pyridine moiety to engage the P1 binding pocket of M Pro for strong binding. 6, 8, 15, [23] [24] [25] [26] [27] [28] [29] [30] Boceprevir has a P1 b-cyclobutylalanyl moiety that displays loose binding to the M Pro P1 binding pocket in its M Pro complex structure, 14-16, 19, 20 which explains its relatively moderate M Pro inhibition potency. In our designed boceprevir derivatives, this site is replaced by opal. In M Pro -boceprevir complex structures, the P2 dimethylcyclopropylproline binds neatly to the M Pro P2 binding pocket. Due to its nice fit to the M Pro P2 binding pocket, this site is maintained as dimethylcyclopropylproline in most designed inhibitors. In a small number of inhibitors, other residues such as (S)-5azaspiro [2, 4] heptane-6-carboxylic acid in MPI37, neopentylglycine in MPI38, b-cyclopropylalanine in MPI39, and cyclohexylalanine in MPI45 at the P2 site are introduced. A previous study has indicated that neopentylglycine, b-cyclopropylalanine and cyclohexylalanine at this site lead to either high M Pro inhibition potency in test tubes (in vitro) or in human host cells that express M Pro (in cellulo). 31 The P3 site is either maintained as tert-butylglycine or replaced by O-tertbutylthreonine. tert-Butylglycine at the P3 site in a peptidyl inhibitor is known to generate high in vitro potency and Otert-butylthreonine is known to cause high in cellulo and antiviral potency. 21, 32 Boceprevir has a P4 N-terminal tert-butylcarbamide cap. This site is either maintained as a carbamide or replaced by a carbamate or amide.

Boceprevir has an a-ketoamide warhead that covalently interacts with the M Pro active site cysteine C145 to generate a hemithioacetal intermediate. Since the majority of currently known peptidyl inhibitors of M Pro have an aldehyde warhead, we replaced the a-ketoamide warhead with an aldehyde in some designed inhibitors. We also tested nitrile at this position since PF-07321332 and some other developed M Pro inhibitors have this warhead. 22, 33 An advantage of the a-ketoamide warhead is its allowance of appending additional chemical moieties at its a-ketoamide nitrogen. All aldehyde-and nitrile-containing inhibitors will leave the M Pro P3' binding pocket empty when they bind to M Pro . A chemical appendage at the a-ketoamide nitrogen can potentially reach this pocket for additional interactions and therefore lead to high affinity to M Pro . MPI31-36 were designed for this purpose. The base molecule of MPI31-36 is MPI30 that is different from boceprevir only at the P1 residue. Please note that MPI30 is a previously developed M Pro inhibitor with a name as ML1000, though the structural characterization of its complex with M Pro has not been reported. 34 We follow typical peptide coupling chemistry to synthesize all inhibitors. In general, the synthesis started from the P4 N-terminal cap to the C-terminal warhead. All compounds were strictly characterized to ensure their purity. Synthetic details and characterizations are provided in the supplementary information.

Kinetic characterizations of MPI29-47 and PF-07321332 on their in vitro enzymatic inhibition potency. In a previous drug repurposing project, we established a protocol to characterize M Pro inhibitors. 12 In this protocol, a fluorogenic substrate Sub3 is used. We followed this protocol to characterize in vitro M Pro inhibition potency for all synthesized inhibitors by determining their IC50 values. To conduct the assay, we preincubated 20 nM M Pro with varied concentrations of an inhibitor for 30 min before 10 µM Sub3 was added and the fluorescent product formation was recorded in a fluorescence plate reader. All inhibitors exhibited well defined inhibition curves that started from 100% activity without an inhibitor and reached to almost total inhibition when 10 µM of an inhibitor was provided. Data are presented in Figure 2 . We fit all collected data to a four-parameter variable slope inhibition equation in GraphPad 9.0 to obtain IC50 values for all inhibitors. Determined IC50 values are presented in Table 1 . As shown in Table 1 , MPI29 has the highest in vitro potency with an IC50 value as 9.3 nM. Since we used 20 nM M Pro for the assay, this IC50 value has reached the detection limit. Real in vitro potency of MPI29 is likely higher than what the determined IC50 value indicates. MPI29 has an aldehyde warhead. MPI30 is different from MPI29 only at the warhead position. It has an a-ketoamide instead. MPI30 has a determined IC50 value as 40 nM. This value is similar to that reported by Westberg et al. 34 This lower potency than MPI29 is expected since aketoamide is less chemically reactive than aldehyde toward a nucleophile. However, MPI30 is 100-fold more potent than boceprevir indicating the essential role of the P1 opal residue in improving interactions with M Pro . MPI31-36 all have much higher in vitro IC50 values than MPI30. Apparently adding a chemical appendage to the a-ketoamide nitrogen leads to less favored interactions with M Pro . Interestingly, MPI33 that has the smallest appendage has an in vitro IC50 value closest to MPI30. Although the benzyl appendage in MPI36 is bigger than that in MPI32-35, it is less detrimental to the in vitro potency indicating that the benzyl group possibly involves some favorable interactions with M Pro in comparison to other N-substituents.

MPI37 is different from MPI29 at the P2 residue. It has a determined in vitro IC50 value as 23 nM. Although replacing the P2 dimethylcyclopropylproline with (S)-5azaspiro [2, 4] heptane-6-carboxylic acid leads to less favorable interactions with M Pro , the effect is not dramatic. A similar observation was made with MPI38 that has a P2 neopentylglycine. MPI39 have both P2 and P3 sites different from MPI29. Both residues in MPI39 have been shown in a previous study favoring interactions with M Pro . 31 Accordingly, we notice that MPI39 has relatively high in vitro potency. MPI40, MPI42 and MPI43 are different from MPI29 only in their P4 N-terminal cap. MPI40 has a P4 N-terminal amide that is different from MPI29 only at one atom position. However, this slight change leads to about 20-fold loss of in vitro potency. Intriguingly, removing one methyl group from the P4 N-terminal cap of MPI40, which leads to MPI42, improves in vitro potency for about 9 folds. Another interesting observation is on MPI43. MPI43 has a P4 N-terminal carbamate and is different from MPI29 and MPI40 only at the carbamate oxygen position. It has in vitro potency between MPI29 and MPI40. Therefore, switching a P4 Nterminal carbamide nitrogen to oxygen is less detrimental to in vitro potency than switching it to methylene. MPI41 is an a-ketoamide derivative of MPI40. It has in vitro potency surprisingly similar to MPI40 although a-ketoamide is expected to be less reactive than aldehyde. MPI44 is different from MPI43 at its P4 N-terminal Oalkyl group. It has a benzyl group instead of a tert-butyl group as in MPI43. Although two O-alkyl groups are structurally different, MPI43 and MPI44 have similar in vitro potency. In our previous work, we noticed that an Obenzyl group at this position loosely binds M Pro . Similar in vitro potency between MPI43 and MPI44 indicates that an O-tert-butyl group at this position might involve loose interactions with M Pro as well. In our previous work, we discovered that MPI8, a peptidyl aldehyde has the highest in cellulo and antiviral potency among all inhibitors that we synthesized. 21, 31 Due to the high in vitro potency of MPI29, we created chimera inhibitors MPI45 and MPI46 that integrate structural components from both MPI8 and MPI29. MPI45 is a chimera in which the P4 N-terminal cap of MPI29 is fused to the rest of MPI8 and MPI46 is a product made by switching the P2 residue in MPI8 to the one in MPI29. Both MPI45 and MPI46 have in vitro potency similar to MPI8 with an IC50 value about 100 nM. 32 MPI47 is different from MPI40 only at its warhead. It has an in vitro IC50 value as 720 nM. Apparently switching the warhead to nitrile from either aldehyde or a-ketoamide leads to significant loss of in vitro potency. Although PF-07321332 and MPI47 are structurally similar, PF-07321332 has a more than 10-folder lower IC50 value than MPI47. A likely explanation is that the P4 N-terminal trifluoroacetamide cap in PF-07321332 involves unique interactions with M Pro that do not exist for MPI47.

In order to structurally characterize our developed inhibitors in their complexes with M Pro . We crystalized M Pro in its apo form and then soaked obtained crystals with our designed inhibitors for X-ray crystallography analysis. Using this approach, we successfully determined 10 M Pro -inhibitor complex structures to high resolutions. These inhibitors include MPI29, MPI30, MPI32-38, and MPI42. PDB entries for these M Pro -inhibitor complex structures are summarized in Table 1 . In the active sites of all M Pro -inhibitor complexes, electron density is well shaped for unambiguous modeling of inhibitors except for MPI36 at the N-benzyl group of its a-ketoamide ( Figure 3A) . A covalent bond between C145 of M Pro and the warhead of an inhibitor is clearly visible in all structures.

In the M Pro -MPI29 complex as shown in Figure 3B , MPI29 forms a number of hydrogen bonds with M Pro . The amide of the P1 opal side chain lactam forms three hydrogen bonds with M Pro residues including F140 at its backbone oxygen, H163 at one of its imidazole nitrogen atoms and E166 at its side chain carboxylate. There are two hydrogen bonds generated between two backbone amides of MPI29 and M Pro residues including H164 at its backbone oxygen and E166 at its backbone nitrogen. The P4 N-terminal carbamide cap of MPI29 uses its two nitrogen atoms to form hydrogen bonds with the backbone oxygen of M Pro E166. In previous published structures of M Pro bound with peptidyl aldehyde inhibitors that have a P4 Nterminal carbamate, typically only one hydrogen bond is observed between the P4 N-terminal cap and M Pro E166. One additional hydrogen bond that is formed between the P4 N-terminal cap and M Pro E166 provides an explanation of very high in vitro potency of MPI29. In the M Pro -MPI29 complex, the hemithioacetal hydroxide is predominantly in an S configuration and poises to interact with three M Pro backbone amide NH groups from G143, S144 and C145 that purportedly generates an oxyanion hole to stabilize the transition state of M Pro -catalyzed hydrolysis of a substrate. This favorable binding of the hemithioacetal hydroxide at the oxyanion hole likely contributes to strong in vitro potency for peptidyl aldehyde inhibitors. In M Pro -MPI29, the P2 dimethylcyclopropylproline is in van der Waals distances to most surrounding M Pro residues in the P2 binding pocket, which indicates favorable hydrophobic interactions. The P3 tert-butylglycine doesn't involve obvious interactions with M Pro residues. However, the tert-butyl group in the P4 N-terminal cap fits nicely to the M Pro binding pocket indicating favorable van der Waals interactions with surrounding M Pro residues. All these favorable interactions likely contribute to the exceedingly high in vitro potency of MPI29.

MPI30 is different from MPI29 only at its warhead. It has an a-ketoamide. In its crystal structure as shown in Figure 2C , MPI30 forms interactions with M Pro similar to MPI29 at the P1, P2 and P3 residues and the P4 N-terminal group. We observed one additional hydrogen bond that is formed between the P4 N-terminal carbamide oxygen and the side chain of M Pro Q189. The keto group of the a-ketoamide of MPI30 covalently interacts with M Pro C145 to generate a hemithioacetal. Unlike MPI29, the hemithioacetal hydroxide adopts a conformation pointing away from the oxyanion hole. It is in an unambiguously S configuration and interacts with H41 through two water-bridged hydrogen bonds. The amide part of the warhead points toward the oxyanion hole. The amide oxygen is assigned at the oxyanion hole due to its ability to form hydrogen bonds with three backbone NH groups from M Pro . The amide nitrogen interacts indirectly with the backbone oxygen of M Pro T26 through two water-bridged hydrogen bonds. All these interactions likely contribute to the high in vitro potency of MPI30.

Since MPI32-36 have an MPI30 base structure and different N-appendages on the a-ketoamide, they are presented together in Figure 3C . Except at the appendage position, all other parts of MPI32-36 interact with M Pro similar to MPI30. We designed MPI32-36 with a hope that their a-ketoamide N-appendages may reach the M Pro P3' binding pocket for favorable interactions. However, all Nappendages have a Z configuration that makes them point away from the M Pro P3' binding pocket. The appendage of MPI35 is long enough to fold back to the M Pro P3' pocket. Since the N-benzyl group of MPI36 has weak electron density around the phenyl ring, it is difficult to assess its interactions with M Pro . Its more favorable in vitro potency than MPI34 and MPI35 is likely due to higher structural rigidity of the N-benzyl group than two flexible N-alkyl groups in MPI34 and MPI35. The indirect interaction between the a-ketoamide nitrogen and M Pro T26 that was observed in the M Pro -MPI30 structure is not observed in M Pro complexes with MPI32-36. All Nappendages occupy the original water position and consequently remove this interaction. This might contribute to low in vitro potency of MPI32-36.

As shown in Figures 3E and 3F , MPI37 and MPI38 interact with M Pro similar to MPI29. The P2 residue in MPI37 occupy slightly less space than that in MPI29. This may contribute to less in vitro potency of MPI37 than MPI29. In M Pro -MPI38, there exists a water molecule that bridges an indirect interaction between the P2 backbone nitrogen and the side chain of M Pro Q189. MPI38 displays an M Pro binding mode very similar to MPI18 that was previously developed and structurally resolved in its complex with M Pro (PDB entry: 7RVR). 31 The only difference is at the P4 N-terminal cap. MPI18 has a P4 N-terminal CBZ group that displays loose binding to M Pro and cannot be unambiguously defined in its M Pro complex structure. However, MPI38 has an Ntert-butylcarbamide cap whose structure can be clearly defined in the M Pro -MPI38 complex. MPI38 is slightly more potent than MPI18. This slightly higher potency might be attributed to more favorable interactions between the P4 N-terminal cap and the M Pro P4 binding pocket.

MPI42 is structurally similar to MPI29 except that it has a P4 N-terminal isovaleramide. As shown in Figure  3G , MPI42 interacts with M Pro similar to MPI29 except at the P4 N-terminal cap. The isovaleramide cap adopts a unique orientation that points deep into the M Pro P4 binding pocket. This is different from most currently known peptidyl aldehyde inhibitors. M Pro naturally prefers a P4 valine in its substrates. Isovaleramide is almost structurally identical to valine except that it doesn't have an aamide. It is apparent that isovaleramide engages favorable interactions with M Pro by binding deep to the M Pro P4 binding pocket. This explains its much higher in vitro potency than MPI40 that has an additional methyl group at the P4 N-terminal cap. The 3,3-dimethylbutamide cap in MPI40 is too bulky to fit into the relatively small M Pro P4 binding pocket.

When expressed in a human cell host, M Pro leads to acute cytotoxicity and drives the host cell to undergo apoptosis. Using this unique feature, we previously developed a cell-based assay to characterize in cellulo potency of M Pro inhibitors. 21 In this assay, an inhibitor with in cellulo potency suppresses cytotoxicity from an M Pro -eGFP fusion protein that is ectopically expressed in 293T cells and consequently leads to host cell survival and enhanced overall expression of M Pro -eGFP that can be characterized by flow cytometry. We consider that this assay is more advantageous over a direct antiviral assay in the characterization of M Pro inhibitors since an inhibitor may block functions of host proteases such as TMPRSS2, furin, and cathepsin L that are critical for SARS-CoV-2 infection and therefore provides false positive in cellulo potency results for M Pro inhibitors. [35] [36] [37] Using this assay, we characterized all synthesized inhibitors. Inhibitor-driven M Pro -eGFP expression data are presented in Figure 4 and the determined in cellulo EC50 values are summarized in Table 1 . MPI29-39 that have a P4 N-terminal carbamide cap all showed low in cellulo potency. Since data for all these inhibitors do not reach a plateau at their highest tested concentrations, their EC50 values can only be estimated as higher than 5 or 10 µM. Although MPI29 has the most in vitro potency among all inhibitors that we synthesized, it has very weak potency in cells. MPI40-42 have a P4 N-terminal amide cap. In comparison to MPI29-39, they showed higher in cellulo potency although their determined EC50 values are in a single digit µM range and therefore are relatively high. MPI43 has a P4 N-terminal carbamate and is different from MPI29 and MPI40 at only one atom position. It has a determined in cellulo EC50 value as 0.37 µM. This in cellulo potency is 20-fold higher than MPI40 and 160fold higher than MPI29. Considering that MPI29, MPI40 and MPI43 are different only at one atom position and MPI29 has much higher in vitro potency than MPI43, their drastically reversed potency in cells is intriguing. These three inhibitors must have very different plasma/cellular stability, cellular permeability, or both. MPI44 has a P4 N-terminal CBZ cap. It has a determined in cellulo EC50 value similar to that of MPI43. Since MPI43 and MPI44 have similar in vitro potency as well, the identity of a P4 N-terminal carbamate seems to have little effect on an inhibitor's in vitro and in cellulo potency. MPI45 and MPI46 each have chemical moieties at two positions that are switched from that in MPI29 to that in MPI8. Both have high in cellulo potency. Their determined EC50 values are 0.74 and 0.14 µM respectively. It is evident that chemical moieties in MPI8 are optimal for high in cellulo potency. The in cellulo potency of MPI45 is much lower than that of MPI46 likely due to its P4 N-terminal carbamide cap. Both MPI47 and PF-07321332 have a P4 N-terminal amide, their determined in cellulo EC50 values are similar to that for MPI40-42 that also contain a P4 N-terminal amide. Much lower in cellulo potency of MPI47 than other four inhibitors is likely attributed to its low in vitro potency. Overall, inhibitors with a P4 N-terminal amide cap tend to have much lower in cellulo potency than that with a P4 N-terminal carbamate and for the two groups of inhibitors, their in vitro potency don't correlate with their in cellulo potency. However, the three warheads aldehyde, aketoamide and nitrile don't generate large discrepancy between in vitro and in cellulo potency of inhibitors.

Three most cellularly potent inhibitors MPI43, MPI44 and MPI45 were advanced to antiviral assays. One inhibitor MPI40 that has low cellular potency was characterized as well as a negative control. To quantify their antiviral EC50 values, we conducted plaque reduction neutralization tests of three SARS-CoV-2 variants including USA-WA1/2020, Beta and Delta in Vero E6 cells for all four inhibitors. We infected Vero E6 cells by virus in the presence of an inhibitor at various concentrations for three days and then quantified viral plaque reduction. Based on viral plaque reduction data, we determined antiviral EC50 values for all inhibitors. MPI40 showed no inhibition at all tested concentrations, which matches its detected low in cellulo potency. All other three inhibitors have high antiviral potency. Their determined antiviral EC50 values are similar and around 1 µM ( Figure 5 and Table 1 ). MPI46 show the most well shaped antiviral data. It inhibits the Delta variants slightly better than the other two SARS-CoV-2 variants.

As a potential repurposed drug for COVID-19, boceprevir provided a high hope during the early phase of the COVID-19 pandemic. However, it is only moderate against SARS-CoV-2. Although it shows inhibition of M Pro , it has very weak potency to inhibit M Pro in a human cell host. 21 Lin et al. made ML1000 (MPI30 in our series) based on boceprevir. Although it showed high in vitro potency, its antiviral potency was minimal. 34 In our study, both MPI29 and MPI30 are highly potent M Pro inhibitors in vitro. The in vitro potency of MPI29 has even reached the detection limit of our kinetic assay. However, both inhibitors show very low in cellulo potency. Except MPI45 that has some MPI8 moieties, all other inhibitors that have a P4 N-terminal carbamide cap all display low in cellulo potency. Based on these data, we can conclude that M Pro inhibitors that have a P4 N-terminal carbamide will have low cellular and antiviral potency. Although reasons for this low cellular and antiviral potency need to be further investigated, the emergency situation of COVID-19 demands to focus on other routes to develop M Pro inhibitors as potential SARS-CoV-2 therapeutics. An alternative to the P4 N-terminal carbamide is amide. We synthesized several inhibitors that contain a P4 N-terminal amide. In comparison to inhibitors that have a P4 N-terminal carbamide, P4 amide-containing inhibitors are relatively more potent in cells but their cellular potency is moderate. However, all three inhibitors with a P4 N-terminal carbamate show high cellular potency and also high antiviral potency. Our collected data support a conclusion that a P4 N-terminal carbamate in a boceprevir-based M Pro inhibitor is required for high cellular and antiviral potency. In other positions, a P1 opal residue, a P2 dimethylcyclopropylproline, and a P3 tert-butylglyine or O-tert-butylthreonine are necessary for high cellular and antiviral potency. In previous work, we discovered that a P3 Otert-butylthreonine is critical for an M Pro inhibitor to have high cellular and antiviral potency. 31 This observation is supported by the high cellular and antiviral potency of MPI46. MPI8 was previously discovered as a highly potent SARS-CoV-2 inhibitor with an EC50 value as 30 nM. 21, 32, 38 All boceprevir-based inhibitors that we developed in this work do not reach the potency of MPI8. To improve cellular and antiviral potency of inhibitors such as MPI43, MPI44 and MPI46, a possible route is to search for alternative O-alkyl groups in the P4 N-terminal carbamate cap for improved binding to the M Pro P4 binding pocket. For the warhead, all current data indicate that aldehyde has the best activity. Changing it to either a-ketoamide or nitrile significantly decreases both in vitro and in cellulo potency of an inhibitor. Compounds with an aldehyde will lead to a concern of cytotoxicity. Cytotoxicity and potency of an aldehyde inhibitor for M Pro needs to be carefully balanced when it is finally applied in animals or human patients.

We synthesized a number of a-ketoamide inhibitors with different alkyl substituents at the a-ketoamide nitrogen. The purpose was to make these N-appendages reach the M Pro P3' binding pocket. Unfortunately, all these inhibitors have low in vitro and in cellulo potency. Structures of their complexes with M Pro all show a Z configuration at the a-ketoamide. It is evident that steric hinderance between the hemithioacetal hydroxide and an N-appendage prevents the N-appendage from adopting a favorable position to interact with the M Pro P3' binding pocket. Although further optimization in related M Pro inhibitors may likely generate interactions with the M Pro P3' binding pocket, we suggest other routes to take advantage of the M Pro P3' binding pocket. In our characterized structures, the P4 N-terminal isovaleramide of MPI42 shows a unique conformation that binds deep into the M Pro P4 binding pocket. This strong binding explains MPI42's much higher in vitro potency than its close relative MPI40. We think MPI42 points to a unique way to develop potent M Pro inhibitors by exploring P4 N-terminal chemical moieties with a similar size as isovaleramide.

Based on our systematic analysis of boceprevir-based M Pro inhibitors, we conclude that a P4 N-terminal carbamate in an inhibitor is critical to yield high cellular and antiviral potency. However, chemical moieties at all sites including the P4 N-terminal carbamate and the warhead might be continuously optimized. Supplementary information for the synthesis of MPI29-47 and PF-07321332, NMR spectroscopy and HPLC chromatography figures, X-ray data collection and processing parameters, and all original flow cytometry graphs. All compounds are >95% pure by HPLC analysis. MPI40 and MPI46 contain two diastereomers. 

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs

PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Bepridil is potent against SARS-CoV-2 in vitro

Virology, transmission, and pathogenesis of SARS-CoV-2

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics

The discovery and development of boceprevir

The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease

M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals

Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics

M<sup>pro</sup> Inhibitor Clinical Candidate for the Treatment of COVID-19

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors

Improved SARS-CoV-2 M(pro) inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L

The P3-O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors, under review for

A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*

Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors

Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects

MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L*